About 100 000 cases of acute hepatitis B virus (HBV) infection occur annually in South America. The overall prevalence of HBV infection in low risk populations ranges from 6.7% to 41%, while hepatitis B surface antigen (HBsAg) rates range from 0.4% to 13%. In high endemicity aboriginal or rural populations, perinatal transmission may play a major part in the spread of HBV. In urban populations, however, horizontal transmission, probably by sexual contact, is the predominant mode of spread, with higher rates of HBV positivity in lower socioeconomic groups. High risk populations such as health care workers and haemodialysis patients show higher rates of HBV infection than comparable populations elsewhere. The risk of posttransfusion hepatitis B remains high in some areas. Concomitant HBV infection may accelerate the chronic liver disease seen in decompensated hepatosplenic schistosomiasis. In the north, the prevalence of hepatitis delta virus (HDV) infection ranks among the highest in the world. In the south, the problem appears negligible although it is increasing within high risk urban communities. HDV superinfection has been the cause of large outbreaks offulminant hepatitis. The cost ofcomprehensive or mass vaccination programmes remains unaffordable for most South American countries. Less expensive alternatives such as low dose intradermal schedules of immunisation have been used with success in selected adult subjects. (Gut 1996; 38 While it is certain that both HBV and HDV infections are highly prevalent in South America, pronounced regional differences in infection and carrier rates do exist, not only among different nations within the area but also -because of racial, geographical, socioeconomic, and other related factors -within individual countries. Thus, in terms of morbidity and mortality, a complex regional mosaic of epidemiological patterns and pathologies emerges.
Viral hepatitis remains an important cause of morbidity and mortality in many Latin American countries, where hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis delta virus (HDV) and, to a lesser degree, hepatitis E virus, have all been reported as aetiological agents of both major regional outbreaks and isolated cases. 1-14 Among these, HBV, HCV, and HDV are the key agents responsible for chronic infection and liver disease.
In common with other developing regions of the world with high rates of viral hepatitis, most South American countries display socioeconomic conditions that favour the occurrence of hepatitis B and other related infections. Such conditions are characterised, among other factors, by a deteriorating public health and educational infrastructure, overcrowding of populations crammed into a few large cities, resulting from uncontrolled internal and external influxes of population, as well as persistent and extreme poverty.4 5 7 10 14-16 While it is certain that both HBV and HDV infections are highly prevalent in South America, pronounced regional differences in infection and carrier rates do exist, not only among different nations within the area but also -because of racial, geographical, socioeconomic, and other related factors -within individual countries. Thus, in terms of morbidity and mortality, a complex regional mosaic of epidemiological patterns and pathologies emerges.
Data limitations
Information on HBV prevalence in different areas of South America remains partial and scarce, at best. Most available data are inherently biased as they originate from blood bank reports, and blood donors are often selected from healthy adult populations. Furthermore, blood banks that perform routine HBV serological screening are mostly located in urban settings, and important differences in testing methodology exist.
Although National Hepatitis Committees have been established to facilitate the accumulation of valuable local data, only limited information exists from any single country with regard to HBV prevalence according to race, age, socioeconomic level or urban/rural status. As most cases of HDV infection occur precisely in rather remote locations, such as the Amazon Basin, where the prevalence of HBV infection is highest, epidemiological information is especially hard to collect. Moreover, the true prevalence of HDV can be difficult to estimate because it increases the severity of chronic liver disease and is also found more frequently in people with chronic HBV liver disease than in asymptomatic HBV carriers. Therefore, to clarify the level of endemicity and the predominant regional patterns of HDV spread, more reliable figures are required on HDV prevalence, both in known HBV carriers and in those people with chronic liver disease.7 13 17 18 The shortcomings of analysing limited epidemiological data are illustrated by two recent surveys of different Peruvian towns.4 10 One such survey showed that the prevalence of antibodies to hepatitis B surface antigen (antiHBs) in coastal towns was very similar to that reported in the main cities, reaching a high of jungle areas showed the highest prevalence of anti-HBs of approximately 86%.4 10 The authors suggested two possible factors to explain these findings: firstly, the proximity of the latter two towns to the Amazonic region; secondly, the probability that, in those areas, HBV infection is acquired at an early age.10
In Huanta (Ayacucho), an Andean city located 2400 metres above sea level, 36 healthy native residents and 100 acute hepatitis patients were evaluated as part of the same study.4 The prevalences of hepatitis B surface antigen (HBsAg) and antibodies to hepatitis B core antigen (anti-HBc) were found to be 5.5% and 30.5%, respectively, among residents, and 2l1% and 53% among patients. Not a single case of HDV infection was reported. In contrast, a similar study carried out among 143 healthy students selected randomly from four schools in the same city only two years later showed a much higher prevalence of HBsAg (16%), and anti-HBc (84.8%), as well as markers of previous HDV infection (17.9% with anti-HDV antibodies).19 SEROLOGICAL ASSAYS Some South American countries currently manufacture their own diagnostic kits for either HBV or HDV. As a result, the serological assays used in each study may vary, further complicating the interpretation of available data. The high cost of diagnostic tests prevents precise identification of the specific virus involved in each reported case, which also affects the quality of surveillance records.
Newly developed serological assays remain out ofreach for most South American countries, and are not expected to be routinely introduced in the near future. They include the new micro ELISA techniques for detection of HBV pre-S1 protein and anti-pre-S2, HBV 16 22-26 Chronic hepatitis B Currently available information on the epidemiology of chronic hepatitis B infection in the region is largely derived from seroprevalence studies in blood donors. According to such studies, the seroprevalence of HBsAg ranges from 0.4% in some areas of Chile up to 13% in northern Brazil, demonstrating a wide spectrum of HBsAg prevalence, not only within the region, but also between different populations of a particular geographical area (Table I) 
Summary
The results of many seroepidemiological surveys suggest that, in hyperendemic regions, the pool of chronic HBV carriers probably arises from perinatal or early childhood infection. On the other hand, studies performed in urban populations with lower HBV carrier rates suggest that sexual transmission is the predominant mode of HBV spread in those areas, and that HBV positive subjects are more often adults than children.2 13 20 Furthermore, some countries have reported a higher prevalence of HBV infection in the poorest urban areas or in lower socioeconomic population segments. 13 17 28 29 53 Generally, the results of the various retrospective and prospective investigations carried out to date suggest that horizontal transmission probably represents the major mode of HBV spread in the main Latin American cities. Undoubtedly, the reported prevalence of HBV in urban areas and in healthy populations is lower than that seen in aborigine populations.2 7 9 12 13 15 19 20 21 27 53 Hepatitis delta epidemiology As HDV is dependent on HBV for its replication, it can only infect those people who are simultaneously infected with HBV (coinfection) or who are already carriers of HBV (super infection). As a result, the distribution and prevalence of HDV in Latin America tend to parallel those of HBV, particularly in populations with overt factors predisposing to parenteral or sexual routes of transmission, such as some Amerindian communities.4-6 9 12 13 15 54 However, as in other less developed tropical areas of the world, the epidemiology of HDV infection in South America is marked by great contrasts. Thus, HDV may cause widespread outbreaks ofboth fulminant and chronic hepatitis in the northern part of the continent, whereas it is virtually absent in other areas with a similar or even higher HBV endemicity.5 12 13 26 54-56 Based on current worldwide estimates, at least 300 000 people in the region (5°/O of the estimated six million HBsAg carriers) are infected with HDV and most are suffering from significant liver disease. ' 20 In some regions, successful efforts have been made to develop and manufacture locally more reliable assays for the detection of HBsAg and anti-HBc. However, standard testing for antiHBc as a surrogate marker for post-transfusion non-A, non-B, non-C hepatitis63 has been implemented in only a few local blood banks. As the prevalence of anti-HBc in South American blood donors and in low risk general populations is relatively high, and HBV-DNA may be documented in the serum of many such subjects,13 35 There is no comprehensive national policy for vaccination of health care workers anywhere in the area but immunisation of personnel at risk is consistently performed in many health centres and in some medical and dental schools. Pilot vaccination projects for health care personnel are also being conducted in many countries,30 40 and cost-benefit studies evaluating the impact of either selective or mass vaccination for hospital and patient-care unit staff have clearly shown the economic advantages of both strategies.39 41 77 However, it has been estimated that the total financial burden derived from both the direct and indirect costs of HBV infection and the vaccination programmes is too high for most Latin American countries, partly because of the high price of commercially available HBV vaccines.41
Low dose immunisation schedules, using either plasma derived or yeast derived vaccines given intradermally, have been tried successfully in Brazilian health care workers78 79 and in Venezuelan medical students.80 Seroconversion rates and levels of anti-HBs achieved after low intradermal doses were comparable to those obtained with standard intramuscular doses. Moreover, 91.4% of vaccinated health workers showed anti-HBs levels over 11 times the cut off level (that is, the level considered a good antibody response) 36 months later. 79 Local vaccine production or access to cheaper sources of HBV vaccines have been proposed as alternative solutions.20 In this respect, a genetically engineered Cuban HBV vaccine is currently being commercialised successfully in several South American countries.8' Ensuring that the market price of HBV vaccines is proportional to the particular economic capabilities of each country in the region is essential if mass control programmes are to be carried out effectively.
SUMMARY
In summary, strategies for global control of HBV in Latin America are similar to those recommended by the WHO worldwide.49 71 82 Universal HBsAg screening of blood and blood products, availability of suitable HBV marker reagents, and an extensive infant HBV immunisation programme integrated into the EPI are three desirable goals. Meanwhile, overall control of HBV infection and its sequelae in South America is urgently awaited.
